HALEON PLC 3.2% potential upside indicated by Jefferies

Broker Ratings

HALEON PLC with ticker (LON:HLN) now has a potential upside of 3.2% according to Jefferies.

Jefferies set a target price of 330 GBX for the company, which when compared to the HALEON PLC share price of 319 GBX at opening today (07/03/2023) indicates a potential upside of 3.2%. Trading has ranged between 241 (52 week low) and 338 (52 week high) with an average of 14,638,684 shares exchanging hands daily. The market capitalisation at the time of writing is £29,920,013,280.

Haleon plc is a consumer healthcare company. The Company’s product portfolio is divided among five categories: Oral Health; Pain Relief; vitamins, minerals and supplements (VMS); Respiratory Health; Digestive Health, and Other. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax and Centrum. In addition, the Company also has local strategic brands, which include TUMS, ENO, Flonase, ChapStick, Emergen-C, Fenbid, Grand-Pa, and Dr.BEST. The Company operates its business units in three regions: North America; Europe, Middle East, and Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC).

Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:

    Forum friendly shortlink: https://1lo.co/yk8X8

      AIM All Share Index